Eli Lilly has announced its second-quarter financial results, showing significant growth driven by sales of its weight-loss drugs Mounjaro and Zepbound. While the company topped earnings and revenue estimates, with a 38% revenue increase to $15.56 billion and Zepbound sales soaring 172% year-over-year, its stock fell 14% following disappointing trial results for a competing obesity drug. Despite overall strong performance and a raised full-year profit forecast, concerns over trial data have overshadowed its achievements.